Combined PET/MRI

Global Warming—Summary Report of the 6th International Workshop on PET/MRI, March 27–29, 2017, Tübingen, Germany

D. L. Bailey, B. J. Pichler, B. Gückel, G. Antoch, H. Barthel, Zaver M Bhujwalla, S. Biskup, S. Biswal, M. Bitzer, R. Boellaard, R. F. Braren, C. Brendle, K. Brindle, A. Chiti, C. la Fougère, R. Gillies, V. Goh, M. Goyen, M. Hacker, L. Heukamp & 16 others G. M. Knudsen, A. M. Krackhardt, I. Law, J. C. Morris, K. Nikolaou, J. Nuyts, Alvaro Ordonez Suarez, K. Pantel, H. H. Quick, K. Riklund, O. Sabri, B. Sattler, E. G.C. Troost, M. Zaiss, L. Zender, Thomas Beyer

Research output: Contribution to journalArticle

Abstract

The 6th annual meeting to address key issues in positron emission tomography (PET)/magnetic resonance imaging (MRI) was held again in Tübingen, Germany, from March 27 to 29, 2017. Over three days of invited plenary lectures, round table discussions and dialogue board deliberations, participants critically assessed the current state of PET/MRI, both clinically and as a research tool, and attempted to chart future directions. The meeting addressed the use of PET/MRI and workflows in oncology, neurosciences, infection, inflammation and chronic pain syndromes, as well as deeper discussions about how best to characterise the tumour microenvironment, optimise the complementary information available from PET and MRI, and how advanced data mining and bioinformatics, as well as information from liquid biomarkers (circulating tumour cells and nucleic acids) and pathology, can be integrated to give a more complete characterisation of disease phenotype. Some issues that have dominated previous meetings, such as the accuracy of MR-based attenuation correction (AC) of the PET scan, were finally put to rest as having been adequately addressed for the majority of clinical situations. Likewise, the ability to standardise PET systems for use in multicentre trials was confirmed, thus removing a perceived barrier to larger clinical imaging trials. The meeting openly questioned whether PET/MRI should, in all cases, be used as a whole-body imaging modality or whether in many circumstances it would best be employed to give an in-depth study of previously identified disease in a single organ or region. The meeting concluded that there is still much work to be done in the integration of data from different fields and in developing a common language for all stakeholders involved. In addition, the participants advocated joint training and education for individuals who engage in routine PET/MRI. It was agreed that PET/MRI can enhance our understanding of normal and disrupted biology, and we are in a position to describe the in vivo nature of disease processes, metabolism, evolution of cancer and the monitoring of response to pharmacological interventions and therapies. As such, PET/MRI is a key to advancing medicine and patient care.

Original languageEnglish (US)
Pages (from-to)4-20
Number of pages17
JournalMolecular Imaging and Biology
Volume20
Issue number1
DOIs
StatePublished - Feb 1 2018

Fingerprint

Positron-Emission Tomography
Germany
Magnetic Resonance Imaging
Education
Circulating Neoplastic Cells
Whole Body Imaging
Aptitude
Tumor Microenvironment
Data Mining
Workflow
Neurosciences
Computational Biology
Chronic Pain
Nucleic Acids
Multicenter Studies
Patient Care
Language
Biomarkers
Medicine
Clinical Trials

Keywords

  • Hybrid imaging
  • Infection
  • Inflammation
  • Molecular imaging
  • MR-PET
  • MRI
  • Multi-parametric imaging
  • Neurology
  • Oncology
  • PET
  • PET/CT
  • PET/MRI
  • Quantification

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Combined PET/MRI : Global Warming—Summary Report of the 6th International Workshop on PET/MRI, March 27–29, 2017, Tübingen, Germany. / Bailey, D. L.; Pichler, B. J.; Gückel, B.; Antoch, G.; Barthel, H.; Bhujwalla, Zaver M; Biskup, S.; Biswal, S.; Bitzer, M.; Boellaard, R.; Braren, R. F.; Brendle, C.; Brindle, K.; Chiti, A.; la Fougère, C.; Gillies, R.; Goh, V.; Goyen, M.; Hacker, M.; Heukamp, L.; Knudsen, G. M.; Krackhardt, A. M.; Law, I.; Morris, J. C.; Nikolaou, K.; Nuyts, J.; Ordonez Suarez, Alvaro; Pantel, K.; Quick, H. H.; Riklund, K.; Sabri, O.; Sattler, B.; Troost, E. G.C.; Zaiss, M.; Zender, L.; Beyer, Thomas.

In: Molecular Imaging and Biology, Vol. 20, No. 1, 01.02.2018, p. 4-20.

Research output: Contribution to journalArticle

Bailey, DL, Pichler, BJ, Gückel, B, Antoch, G, Barthel, H, Bhujwalla, ZM, Biskup, S, Biswal, S, Bitzer, M, Boellaard, R, Braren, RF, Brendle, C, Brindle, K, Chiti, A, la Fougère, C, Gillies, R, Goh, V, Goyen, M, Hacker, M, Heukamp, L, Knudsen, GM, Krackhardt, AM, Law, I, Morris, JC, Nikolaou, K, Nuyts, J, Ordonez Suarez, A, Pantel, K, Quick, HH, Riklund, K, Sabri, O, Sattler, B, Troost, EGC, Zaiss, M, Zender, L & Beyer, T 2018, 'Combined PET/MRI: Global Warming—Summary Report of the 6th International Workshop on PET/MRI, March 27–29, 2017, Tübingen, Germany', Molecular Imaging and Biology, vol. 20, no. 1, pp. 4-20. https://doi.org/10.1007/s11307-017-1123-5
Bailey, D. L. ; Pichler, B. J. ; Gückel, B. ; Antoch, G. ; Barthel, H. ; Bhujwalla, Zaver M ; Biskup, S. ; Biswal, S. ; Bitzer, M. ; Boellaard, R. ; Braren, R. F. ; Brendle, C. ; Brindle, K. ; Chiti, A. ; la Fougère, C. ; Gillies, R. ; Goh, V. ; Goyen, M. ; Hacker, M. ; Heukamp, L. ; Knudsen, G. M. ; Krackhardt, A. M. ; Law, I. ; Morris, J. C. ; Nikolaou, K. ; Nuyts, J. ; Ordonez Suarez, Alvaro ; Pantel, K. ; Quick, H. H. ; Riklund, K. ; Sabri, O. ; Sattler, B. ; Troost, E. G.C. ; Zaiss, M. ; Zender, L. ; Beyer, Thomas. / Combined PET/MRI : Global Warming—Summary Report of the 6th International Workshop on PET/MRI, March 27–29, 2017, Tübingen, Germany. In: Molecular Imaging and Biology. 2018 ; Vol. 20, No. 1. pp. 4-20.
@article{946956003c834dd3ab00e84058fd1530,
title = "Combined PET/MRI: Global Warming—Summary Report of the 6th International Workshop on PET/MRI, March 27–29, 2017, T{\"u}bingen, Germany",
abstract = "The 6th annual meeting to address key issues in positron emission tomography (PET)/magnetic resonance imaging (MRI) was held again in T{\"u}bingen, Germany, from March 27 to 29, 2017. Over three days of invited plenary lectures, round table discussions and dialogue board deliberations, participants critically assessed the current state of PET/MRI, both clinically and as a research tool, and attempted to chart future directions. The meeting addressed the use of PET/MRI and workflows in oncology, neurosciences, infection, inflammation and chronic pain syndromes, as well as deeper discussions about how best to characterise the tumour microenvironment, optimise the complementary information available from PET and MRI, and how advanced data mining and bioinformatics, as well as information from liquid biomarkers (circulating tumour cells and nucleic acids) and pathology, can be integrated to give a more complete characterisation of disease phenotype. Some issues that have dominated previous meetings, such as the accuracy of MR-based attenuation correction (AC) of the PET scan, were finally put to rest as having been adequately addressed for the majority of clinical situations. Likewise, the ability to standardise PET systems for use in multicentre trials was confirmed, thus removing a perceived barrier to larger clinical imaging trials. The meeting openly questioned whether PET/MRI should, in all cases, be used as a whole-body imaging modality or whether in many circumstances it would best be employed to give an in-depth study of previously identified disease in a single organ or region. The meeting concluded that there is still much work to be done in the integration of data from different fields and in developing a common language for all stakeholders involved. In addition, the participants advocated joint training and education for individuals who engage in routine PET/MRI. It was agreed that PET/MRI can enhance our understanding of normal and disrupted biology, and we are in a position to describe the in vivo nature of disease processes, metabolism, evolution of cancer and the monitoring of response to pharmacological interventions and therapies. As such, PET/MRI is a key to advancing medicine and patient care.",
keywords = "Hybrid imaging, Infection, Inflammation, Molecular imaging, MR-PET, MRI, Multi-parametric imaging, Neurology, Oncology, PET, PET/CT, PET/MRI, Quantification",
author = "Bailey, {D. L.} and Pichler, {B. J.} and B. G{\"u}ckel and G. Antoch and H. Barthel and Bhujwalla, {Zaver M} and S. Biskup and S. Biswal and M. Bitzer and R. Boellaard and Braren, {R. F.} and C. Brendle and K. Brindle and A. Chiti and {la Foug{\`e}re}, C. and R. Gillies and V. Goh and M. Goyen and M. Hacker and L. Heukamp and Knudsen, {G. M.} and Krackhardt, {A. M.} and I. Law and Morris, {J. C.} and K. Nikolaou and J. Nuyts and {Ordonez Suarez}, Alvaro and K. Pantel and Quick, {H. H.} and K. Riklund and O. Sabri and B. Sattler and Troost, {E. G.C.} and M. Zaiss and L. Zender and Thomas Beyer",
year = "2018",
month = "2",
day = "1",
doi = "10.1007/s11307-017-1123-5",
language = "English (US)",
volume = "20",
pages = "4--20",
journal = "Molecular Imaging and Biology",
issn = "1536-1632",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Combined PET/MRI

T2 - Global Warming—Summary Report of the 6th International Workshop on PET/MRI, March 27–29, 2017, Tübingen, Germany

AU - Bailey, D. L.

AU - Pichler, B. J.

AU - Gückel, B.

AU - Antoch, G.

AU - Barthel, H.

AU - Bhujwalla, Zaver M

AU - Biskup, S.

AU - Biswal, S.

AU - Bitzer, M.

AU - Boellaard, R.

AU - Braren, R. F.

AU - Brendle, C.

AU - Brindle, K.

AU - Chiti, A.

AU - la Fougère, C.

AU - Gillies, R.

AU - Goh, V.

AU - Goyen, M.

AU - Hacker, M.

AU - Heukamp, L.

AU - Knudsen, G. M.

AU - Krackhardt, A. M.

AU - Law, I.

AU - Morris, J. C.

AU - Nikolaou, K.

AU - Nuyts, J.

AU - Ordonez Suarez, Alvaro

AU - Pantel, K.

AU - Quick, H. H.

AU - Riklund, K.

AU - Sabri, O.

AU - Sattler, B.

AU - Troost, E. G.C.

AU - Zaiss, M.

AU - Zender, L.

AU - Beyer, Thomas

PY - 2018/2/1

Y1 - 2018/2/1

N2 - The 6th annual meeting to address key issues in positron emission tomography (PET)/magnetic resonance imaging (MRI) was held again in Tübingen, Germany, from March 27 to 29, 2017. Over three days of invited plenary lectures, round table discussions and dialogue board deliberations, participants critically assessed the current state of PET/MRI, both clinically and as a research tool, and attempted to chart future directions. The meeting addressed the use of PET/MRI and workflows in oncology, neurosciences, infection, inflammation and chronic pain syndromes, as well as deeper discussions about how best to characterise the tumour microenvironment, optimise the complementary information available from PET and MRI, and how advanced data mining and bioinformatics, as well as information from liquid biomarkers (circulating tumour cells and nucleic acids) and pathology, can be integrated to give a more complete characterisation of disease phenotype. Some issues that have dominated previous meetings, such as the accuracy of MR-based attenuation correction (AC) of the PET scan, were finally put to rest as having been adequately addressed for the majority of clinical situations. Likewise, the ability to standardise PET systems for use in multicentre trials was confirmed, thus removing a perceived barrier to larger clinical imaging trials. The meeting openly questioned whether PET/MRI should, in all cases, be used as a whole-body imaging modality or whether in many circumstances it would best be employed to give an in-depth study of previously identified disease in a single organ or region. The meeting concluded that there is still much work to be done in the integration of data from different fields and in developing a common language for all stakeholders involved. In addition, the participants advocated joint training and education for individuals who engage in routine PET/MRI. It was agreed that PET/MRI can enhance our understanding of normal and disrupted biology, and we are in a position to describe the in vivo nature of disease processes, metabolism, evolution of cancer and the monitoring of response to pharmacological interventions and therapies. As such, PET/MRI is a key to advancing medicine and patient care.

AB - The 6th annual meeting to address key issues in positron emission tomography (PET)/magnetic resonance imaging (MRI) was held again in Tübingen, Germany, from March 27 to 29, 2017. Over three days of invited plenary lectures, round table discussions and dialogue board deliberations, participants critically assessed the current state of PET/MRI, both clinically and as a research tool, and attempted to chart future directions. The meeting addressed the use of PET/MRI and workflows in oncology, neurosciences, infection, inflammation and chronic pain syndromes, as well as deeper discussions about how best to characterise the tumour microenvironment, optimise the complementary information available from PET and MRI, and how advanced data mining and bioinformatics, as well as information from liquid biomarkers (circulating tumour cells and nucleic acids) and pathology, can be integrated to give a more complete characterisation of disease phenotype. Some issues that have dominated previous meetings, such as the accuracy of MR-based attenuation correction (AC) of the PET scan, were finally put to rest as having been adequately addressed for the majority of clinical situations. Likewise, the ability to standardise PET systems for use in multicentre trials was confirmed, thus removing a perceived barrier to larger clinical imaging trials. The meeting openly questioned whether PET/MRI should, in all cases, be used as a whole-body imaging modality or whether in many circumstances it would best be employed to give an in-depth study of previously identified disease in a single organ or region. The meeting concluded that there is still much work to be done in the integration of data from different fields and in developing a common language for all stakeholders involved. In addition, the participants advocated joint training and education for individuals who engage in routine PET/MRI. It was agreed that PET/MRI can enhance our understanding of normal and disrupted biology, and we are in a position to describe the in vivo nature of disease processes, metabolism, evolution of cancer and the monitoring of response to pharmacological interventions and therapies. As such, PET/MRI is a key to advancing medicine and patient care.

KW - Hybrid imaging

KW - Infection

KW - Inflammation

KW - Molecular imaging

KW - MR-PET

KW - MRI

KW - Multi-parametric imaging

KW - Neurology

KW - Oncology

KW - PET

KW - PET/CT

KW - PET/MRI

KW - Quantification

UR - http://www.scopus.com/inward/record.url?scp=85040658227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040658227&partnerID=8YFLogxK

U2 - 10.1007/s11307-017-1123-5

DO - 10.1007/s11307-017-1123-5

M3 - Article

VL - 20

SP - 4

EP - 20

JO - Molecular Imaging and Biology

JF - Molecular Imaging and Biology

SN - 1536-1632

IS - 1

ER -